The chemical class known as SNAT6 inhibitors encompasses a diverse range of compounds that can affect the function of the sodium-coupled neutral amino acid transporter 6 (SNAT6). These inhibitors are not a homogeneous group but are characterized by their ability to interfere with the transport activity of SNAT6, which is integral to the regulation of amino acid homeostasis in cells. The methods by which these inhibitors can act are varied, reflecting the complexity of cellular transport mechanisms. Some inhibitors operate by disrupting the sodium gradient, which is a driving force for the transport function of SNAT6. Others can influence the transporter indirectly by modulating cellular metabolic pathways, which, in turn, can alter the functionality of SNAT6. The action of these inhibitors can affect the transporter's ability to maintain the necessary equilibrium of amino acids within the cell, which is essential for numerous cellular processes, including protein synthesis and metabolic signaling.
The inhibition of SNAT6 can be brought about by alterations in membrane potential or by changing the transporter's immediate cellular environment. Compounds that affect the sodium gradient or cellular pH can alter the electrochemical conditions necessary for SNAT6 to function correctly. Additionally, some inhibitors act on the energy metabolism within the cell, either by uncoupling oxidative phosphorylation or by affecting pathways that regulate nutrient sensing, thus impacting the activity of SNAT6 indirectly. These inhibitors can also influence the transporter by affecting the glycosylation and proper localization of SNAT6 within the cellular membrane. The effects of these compounds are wide-ranging, extending from the initial transporter-ligand interaction to the broader cellular regulatory mechanisms that govern transporter expression and activity. The study of SNAT6 inhibitors is thus closely tied to understanding the fundamental principles governing cellular transport dynamics and the maintenance of amino acid levels within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $506.00 | |||
A cardiac glycoside that inhibits the Na⁺/K⁺-ATPase pump, potentially altering the sodium gradient and could possibly inhibit SNAT6-dependent transport. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
A diuretic that blocks epithelial sodium channels, which could lead to changes in the cellular sodium gradient and could possibly inhibit SNAT6 activity. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $63.00 $250.00 | 13 | |
A dihydrochalcone that inhibits various transport proteins and could alter the membrane potential or cellular environment in a way that could possibly inhibit SNAT6 function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
An ionophore that disrupts sodium homeostasis, which may lead to a decrease in SNAT6-mediated amino acid transport. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $92.00 $348.00 | 46 | |
A protonophore that uncouples oxidative phosphorylation, potentially affecting energy-dependent transport systems including SNAT6. | ||||||
2,4-Dinitrophenol, wetted | 51-28-5 | sc-238345 | 250 mg | $58.00 | 2 | |
An uncoupler of oxidative phosphorylation that might reduce the energy availability for SNAT6's secondary active transport mechanism. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
A glucose transporter 1 (GLUT1) inhibitor that could alter cellular glucose levels, potentially impacting SNAT6 function due to changes in metabolic status. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
A specific inhibitor of the vacuolar type H⁺-ATPase that can disrupt lysosomal acidification, possibly affecting the cellular environment and could possibly inhibit SNAT6. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An inhibitor of N-linked glycosylation that can affect protein folding and trafficking, potentially impacting the proper localization and function of SNAT6. | ||||||